Loading clinical trials...
Loading clinical trials...
Browse 9,450 clinical trials for leukemia. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 1-20 of 9,450 trials
NCT07589829
Purpose: The purpose of this study is to evaluate the clinical, radiological, and biomechanical effects of Kinesio Taping (KT) when integrated into a standard exercise program for individuals with Hallux Valgus (HV). Hallux valgus is a progressive deformity of the first metatarsophalangeal (MTP) joint that leads to pain, functional impairment, and gait disturbances. While conservative treatments like exercises are common, the specific impact of KT on dynamic plantar pressure distribution and radiological angles requires further objective evidence. Methods: A total of 50 participants (aged 18-65) with mild-to-moderate HV are randomized into two groups. Group 1 receives a 4-week intervention consisting of specialized Kinesio Taping applied once a week plus a daily home exercise program. Group 2 performs the same home exercise program only. Assessments: Assessments include radiological measurements (Hallux Valgus Angle - HVA and Intermetatarsal Angle - IMA), clinical pain levels via the Visual Analog Scale (VAS), functional status via the American Orthopaedic Foot and Ankle Society (AOFAS-MTP-IP) scale, and dynamic pedobarographic analysis using the Zebris® FDM-2 system. Physical exercise capacity is also measured by the 6-Minute Walk Test (6MWT).
NCT06317649
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.